Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BBO-8520 by BridgeBio Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
BBO-8520 is under clinical development by BridgeBio Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Acoramidis hydrochloride by BridgeBio Pharma for Familial Amyloid Cardiomyopathy: Likelihood of Approval
Acoramidis hydrochloride is under clinical development by BridgeBio Pharma and currently in Pre-Registration for Familial Amyloid Cardiomyopathy. According to GlobalData,...
Encaleret by BridgeBio Pharma for Autosomal Dominant Hypocalcemia: Likelihood of Approval
Encaleret is under clinical development by BridgeBio Pharma and currently in Phase III for Autosomal Dominant Hypocalcemia. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's Acoramidis hydrochloride?
Acoramidis hydrochloride is a small molecule commercialized by BridgeBio Pharma, with a leading Pre-Registration program in Familial Amyloid Cardiomyopathy. According...
Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's BBP-631?
BBP-631 is a gene therapy commercialized by BridgeBio Pharma, with a leading Phase II program in Congenital Adrenal Hyperplasia (Adrenogenital...
Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's Ribitol?
Ribitol is a small molecule commercialized by BridgeBio Pharma, with a leading Phase III program in Limb-Girdle Muscular Dystrophy. According...